e-learning
resources
Stockholm 2007
Monday 17.09.2007
Rare tumours, risk factors and epidemiology in thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Survival time in patients with malignant pleural mesothelioma
E. Mylonaki, A. Ioannidou, T. Tsiouda, E. Kalaitzidou, A. Kosma, A. Kapetangiorgis, V. Voutsas, T. Kontakiotis, N. Galanis, K. Zarogoulidis, P. Christaki (Thessaloniki, Greece)
Source:
Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology
Session:
Rare tumours, risk factors and epidemiology in thoracic oncology
Session type:
Thematic Poster Session
Number:
2506
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Mylonaki, A. Ioannidou, T. Tsiouda, E. Kalaitzidou, A. Kosma, A. Kapetangiorgis, V. Voutsas, T. Kontakiotis, N. Galanis, K. Zarogoulidis, P. Christaki (Thessaloniki, Greece). Survival time in patients with malignant pleural mesothelioma. Eur Respir J 2007; 30: Suppl. 51, 2506
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Malignant pleural mesothelioma clinical aspects and survival in 93 cases
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival
Source: Eur Respir J 2002; 20: Suppl. 38, 272s
Year: 2002
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma?
Source: Eur Respir J 2003; 22: Suppl. 45, 29s
Year: 2003
Bevacizumab-targeted therapy for malignant pleural mesothelioma
Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs
Year: 2017
Management of malignant pleural mesothelioma
Source: Hands-on Course 2012 - Medical Thoracoscopy
Year: 2012
Management of malignant pleural mesothelioma
Source: ERS Skills Course 2015
Year: 2015
Management of malignant pleural mesothelioma
Source: Hands-on Course 2013 - Medical Thoracoscopy
Year: 2013
Management of malignant pleural mesothelioma
Source: School Course 2014 - Medical Thoracoscopy
Year: 2014
Management of malignant pleural mesothelioma
Source: ERS Course 2016 - Skills course on medical thoracoscopy
Year: 2016
Chemotherapy for treatment of malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004
Pathological diagnosis of malignant pleural mesothelioma
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020
Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients
Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases
Year: 2009
Predictors of survival in patients with recurrent malignant pleural effusion
Source: Annual Congress 2008 - Diagnostic and therapeutic approaches in pleural diseases
Year: 2008
PET predicts survival in malignant pleural mesothelioma
Source: ISSN=ISSN 1810-6838, ISBN=, page=290
Year: 2007
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Diagnosis of malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 527s
Year: 2004
Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients
Source: Eur Respir J 2011; 38: 1425-1430
Year: 2011
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept